Inflarx (NASDAQ:IFRX) had its price objective upped by analysts at JPMorgan Chase & Co. from $42.00 to $65.00 in a research note issued on Tuesday, February 5th, The Fly reports. The brokerage presently has a “top pick” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 86.73% from the company’s previous close.
Several other equities analysts have also weighed in on IFRX. Zacks Investment Research lowered Inflarx from a “buy” rating to a “hold” rating in a report on Wednesday, January 30th. ValuEngine raised Inflarx from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Credit Suisse Group assumed coverage on Inflarx in a report on Monday, December 10th. They set an “outperform” rating and a $47.00 price objective for the company. Finally, Robert W. Baird started coverage on Inflarx in a report on Monday, January 28th. They set an “outperform” rating and a $62.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Inflarx presently has a consensus rating of “Buy” and an average target price of $51.67.
Shares of Inflarx stock traded up $1.91 on Tuesday, hitting $34.81. The company had a trading volume of 90,600 shares, compared to its average volume of 87,156. The company has a market cap of $784.24 million, a PE ratio of -11.84 and a beta of -0.94. Inflarx has a 1 year low of $20.31 and a 1 year high of $42.83.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IFRX. Millennium Management LLC increased its holdings in shares of Inflarx by 18.1% in the fourth quarter. Millennium Management LLC now owns 72,153 shares of the company’s stock worth $2,624,000 after buying an additional 11,080 shares during the period. Paloma Partners Management Co bought a new stake in shares of Inflarx in the fourth quarter worth about $526,000. RA Capital Management LLC grew its stake in shares of Inflarx by 6.0% in the fourth quarter. RA Capital Management LLC now owns 2,085,089 shares of the company’s stock worth $75,835,000 after purchasing an additional 117,241 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Inflarx in the fourth quarter worth about $657,000. Finally, Polar Capital LLP grew its stake in shares of Inflarx by 54.4% in the fourth quarter. Polar Capital LLP now owns 141,887 shares of the company’s stock worth $5,160,000 after purchasing an additional 50,000 shares during the last quarter. Institutional investors and hedge funds own 56.70% of the company’s stock.
Inflarx Company Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Further Reading: Diversification in Your Portfolio
Receive News & Ratings for Inflarx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inflarx and related companies with MarketBeat.com’s FREE daily email newsletter.